Anxo Pharmaceutical Co., Ltd. (TPEX:6677)

Anxo Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	314.32	358.92	295.43	241.32	214.18	207.76
Short-Term Investments	-	2.23	89.75	-	-	-
Cash & Short-Term Investments	314.32	361.14	385.18	241.32	214.18	207.76
Cash Growth	-10.14%	-6.24%	59.61%	12.67%	3.09%	16.96%
Accounts Receivable	197.98	210.5	249.71	240.86	208.64	191.06
Other Receivables	6.97	4.67	11.36	10.63	10.42	10.26
Receivables	204.95	215.17	261.07	251.49	219.07	201.32
Inventory	263.94	262.42	283.86	243.1	238.88	267.03
Prepaid Expenses	14.71	18.15	22.19	14.88	17.11	10.96
Other Current Assets	25.98	21.69	25.99	20.7	15.54	17.61
Total Current Assets	823.89	878.56	978.29	771.5	704.78	704.69
Property, Plant & Equipment	1,039	1,038	1,079	1,110	1,140	1,152
Long-Term Investments	52.56	52.56	30	-	-	-
Goodwill	36.61	36.61	36.61	36.61	36.61	36.61
Other Intangible Assets	8.38	9.84	3.77	4.95	4.3	5.01
Long-Term Deferred Tax Assets	41.71	34.38	22.03	18.75	11.77	7.45
Other Long-Term Assets	49.54	57.8	68.82	32.79	21.81	7.55
Total Assets	2,052	2,108	2,219	1,974	1,919	1,913
Accounts Payable	62.61	81.55	79.69	94.03	78.43	76.79
Accrued Expenses	71.84	88.43	75.35	71.58	66.73	73.94
Short-Term Debt	220	205	215	256.38	215	199.63
Current Portion of Long-Term Debt	61.6	63.46	58.5	57.55	64.68	56.82
Current Portion of Leases	13.48	9.36	14.65	11.5	8.69	8.04
Current Income Taxes Payable	-	-	6.68	6.76	4.33	2.09
Current Unearned Revenue	22.04	20.07	5.43	14.47	5.04	12.39
Other Current Liabilities	39.18	34.76	31.42	42.8	29.95	36.17
Total Current Liabilities	490.75	502.61	486.72	555.07	472.84	465.87
Long-Term Debt	412.78	437.61	480.7	528.08	572.61	622.25
Long-Term Leases	10.97	11.2	19	33.57	21.49	2.35
Long-Term Unearned Revenue	16.11	16.21	27.73	26.49	18.09	9.94
Other Long-Term Liabilities	1.34	0.58	1.19	1.26	2.02	1.34
Total Liabilities	931.96	968.21	1,015	1,144	1,087	1,102
Common Stock	558.71	558.14	556.64	481.64	481.64	458.7
Additional Paid-In Capital	459.03	483.68	478.85	211.08	206.62	205.91
Retained Earnings	-20.27	-25.46	54.01	32.14	44.7	48.4
Comprehensive Income & Other	6	6	-	-	-	-
Total Common Equity	1,003	1,022	1,089	724.86	732.96	713.02
Minority Interest	116.27	117	113.76	104.78	98.99	98.44
Shareholders' Equity	1,120	1,139	1,203	829.64	831.94	811.46
Total Liabilities & Equity	2,052	2,108	2,219	1,974	1,919	1,913
Total Debt	718.83	726.63	787.84	887.09	882.47	889.08
Net Cash (Debt)	-404.51	-365.49	-402.66	-645.76	-668.29	-681.32
Net Cash Per Share	-7.25	-6.56	-7.81	-13.41	-13.78	-14.18
Filing Date Shares Outstanding	55.87	55.81	55.66	48.16	48.16	48.16
Total Common Shares Outstanding	55.87	55.81	55.66	48.16	48.16	48.16
Working Capital	333.14	375.94	491.57	216.43	231.93	238.82
Book Value Per Share	17.96	18.32	19.57	15.05	15.22	14.80
Tangible Book Value	958.48	975.92	1,049	683.3	692.04	671.4
Tangible Book Value Per Share	17.16	17.49	18.85	14.19	14.37	13.94
Land	576.53	576.53	576.53	576.53	576.53	576.53
Buildings	418.52	417.99	417.99	416.05	417.89	416.12
Machinery	488.35	463.03	464.55	434.6	436.82	410.26
Construction In Progress	8.51	9.88	-	-	-	-
Leasehold Improvements	14.93	15.9	3.99	2.02	10.09	9.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.